Literature DB >> 21703814

Effectiveness of extracorporeal membrane oxygenation when conventional ventilation fails: valuable option or vague remedy?

Ravindranath Tiruvoipati1, John Botha, Giles Peek.   

Abstract

The mortality and morbidity of patients with severe acute respiratory distress syndrome (ARDS) remains high despite the advances in intensive care practice. The low-tidal-volume ventilation strategy (ARDS net protocol) has been shown to be effective in improving survival. Unfortunately, however, some patients have such severe ARDS that they cannot be managed with the ARDS net strategy. In these patients, rescue therapies such as high-frequency ventilation, prone ventilation, nitric oxide, and extracorporeal membrane oxygenation (ECMO) are considered. The CESAR trial has shown that an ECMO-based protocol improved survival without severe disability as compared with conventional ventilation. The recent increased incidence of severe respiratory failure due to H1N1 influenza pandemic has led to an increased use of ECMO. Although several reports showed ECMO use to be encouraging, some scepticism remains. In this article, we reviewed the usefulness of ECMO in patients with severe ARDS in the light of current evidence. Crown
Copyright © 2012. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21703814     DOI: 10.1016/j.jcrc.2011.04.003

Source DB:  PubMed          Journal:  J Crit Care        ISSN: 0883-9441            Impact factor:   3.425


  7 in total

1.  Continuous renal replacement therapy (CRRT) attenuates myocardial inflammation and mitochondrial injury induced by venovenous extracorporeal membrane oxygenation (VV ECMO) in a healthy piglet model.

Authors:  Juanhong Shen; Wenkui Yu; Qiyi Chen; Jialiang Shi; Yimin Hu; Juanjuan Zhang; Tao Gao; Fengchan Xi; Changsheng He; Jianfeng Gong; Ning Li; Jieshou Li
Journal:  Inflammation       Date:  2013-10       Impact factor: 4.092

2.  C1P Attenuates Lipopolysaccharide-Induced Acute Lung Injury by Preventing NF-κB Activation in Neutrophils.

Authors:  Kristin Baudiß; Rodolfo de Paula Vieira; Sanja Cicko; Korcan Ayata; Madelon Hossfeld; Nicolas Ehrat; Antonio Gómez-Muñoz; Holger K Eltzschig; Marco Idzko
Journal:  J Immunol       Date:  2016-01-22       Impact factor: 5.422

3.  Effect of venovenous extracorporeal membrane oxygenation on the heart in a healthy piglet model.

Authors:  Juanhong Shen; Wenkui Yu; Jialiang Shi; Qiyi Chen; Yimin Hu; Juanjuan Zhang; Tao Gao; Fengchan Xi; Jianfeng Gong; Changsheng He; Ning Li; Jieshou Li
Journal:  J Cardiothorac Surg       Date:  2013-06-28       Impact factor: 1.637

4.  Prediction of mortality in adult patients with severe acute lung failure receiving veno-venous extracorporeal membrane oxygenation: a prospective observational study.

Authors:  Tone Enger; Alois Philipp; Vibeke Videm; Matthias Lubnow; Alexander Wahba; Marcus Fischer; Christof Schmid; Thomas Bein; Thomas Müller
Journal:  Crit Care       Date:  2014-04-09       Impact factor: 9.097

5.  Efficacy of veno-venous extracorporeal membrane oxygenation in severe acute respiratory failure.

Authors:  Jae Jun Lee; Sung Mi Hwang; Jae Houn Ko; Hyoung Soo Kim; Kyung Soon Hong; Hyun Hee Choi; Myung Goo Lee; Chang Youl Lee; Won Ki Lee; Eun Jin Soun; Tae Hun Lee; Jeong Yeol Seo
Journal:  Yonsei Med J       Date:  2015-01       Impact factor: 2.759

6.  Performance of Multiple Risk Assessment Tools to Predict Mortality for Adult Respiratory Distress Syndrome with Extracorporeal Membrane Oxygenation Therapy: An External Validation Study Based on Chinese Single-center Data.

Authors:  Lei Huang; Tong Li; Lei Xu; Xiao-Min Hu; Da-Wei Duan; Zhi-Bo Li; Xin-Jing Gao; Jun Li; Peng Wu; Ying-Wu Liu; Song Wang; Yu-Heng Lang
Journal:  Chin Med J (Engl)       Date:  2016-07-20       Impact factor: 2.628

7.  Interhospital transfer of seriously sick ARDS patients using veno-venous Extracorporeal Membrane Oxygenation (ECMO): Concept of an ECMO transport team.

Authors:  Christoph T Starck; Peter Hasenclever; Volkmar Falk; Markus J Wilhelm
Journal:  Int J Crit Illn Inj Sci       Date:  2013-01
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.